NEW YORK (GenomeWeb News) – Australian molecular diagnostics firm Genetic Technologies today announced plans to raise about US$9.6 million.

The fund raising will take place in three tranches and net proceeds will be used to expand US distribution of GTG's BrevaGen breast cancer test, and to complete additional studies to add new ethnic groups — Hispanic- and African-Americans — in order to expand the test's addressable market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.